Research.Patient.info

Patients with relapsed/refractory symptomatic multiple myeloma (MM) research hub

1 indexed studies · 0 currently recruiting

authorisedTherapeutic exploratory (Phase II)
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)
This study is looking at a new combination of medicines - mezigdomide, carfilzomib, and dexamethasone - for people with multiple myeloma that has come back or isn't responding to other treatments. It wants to see how well this new treatment works.
France